Anti-mitotic chemotherapeutics promote apoptosis through TL1A-activated death receptor 3 in cancer cells

Cell Research
Chen QiGelin Wang

Abstract

The commonly used antimitotic chemotherapeutic agents such as taxol and vinblastine arrest cell cycle progression by disrupting mitotic spindles, and cause cancer cells to undergo apoptosis through 'mitotic catastrophe'. The molecular mechanisms by which these drugs induce apoptosis and their relevance to clinical efficacy are not known. Facilitated by a new spindle poison diazonamide, we found that apoptosis induced by these agents requires death receptor 3 (DR3). Mitotic arrest by these agents induces lysosome-dependent secretion of the DR3 ligand, TL1A. Engagement of TL1A with DR3 stimulates the formation of FADD-containing and caspase-8-containing death-inducing signaling complex (DISC), which subsequently activates apoptosis in cells that express DR3. Expression of DR3 and TL1A correlates with the apoptotic response of human tumor xenograft models and human cancer cell lines to antimitotic drugs, providing further evidence that these drugs kill cancer cells through the DR3/TL1A-mediated pathway. These results suggest that TL1A and DR3 may hold promise to be used as biomarkers for predicting clinical response to antimitotic therapeutics.

References

Oct 11, 1996·Science·Y Li, R Benezra
Apr 29, 1997·Proceedings of the National Academy of Sciences of the United States of America·G R ScreatonJ I Bell
May 20, 1998·Current Biology : CB·S A MarstersA Ashkenazi
Aug 28, 1998·Science·A Ashkenazi, V M Dixit
Aug 28, 1998·Science·N A Thornberry, Y Lazebnik
Apr 21, 1999·Current Opinion in Cell Biology·A Ashkenazi, V M Dixit
Nov 17, 2001·Current Opinion in Pharmacology·K W WoodJ R Jackson
Jan 5, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Masafumi NakayamaHideo Yagita
Dec 10, 2003·Oncogene·Kapil N Bhalla
Apr 2, 2004·Nature Reviews. Cancer·Mary Ann Jordan, Leslie Wilson
Apr 13, 2004·Oncogene·Maria CastedoGuido Kroemer
Jun 11, 2004·Annual Review of Biochemistry·Xuejun Jiang, Xiaodong Wang
Jun 7, 2005·Cell·Douglas R Green
Jan 26, 2007·Nature Reviews. Cancer·Jeffrey R JacksonPearl S Huang
Feb 9, 2007·Proceedings of the National Academy of Sciences of the United States of America·Noelle S WilliamsSteven L McKnight
Feb 9, 2007·Proceedings of the National Academy of Sciences of the United States of America·Gelin WangXiaodong Wang
Feb 26, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Karl-Ludwig SchaeferChristopher Poremba
Jul 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey NealePeter J Houghton
Feb 2, 2011·Nature Reviews. Clinical Oncology·Edina Komlodi-PasztorTito Fojo
Mar 9, 2011·Nature Medicine·Lynda ChinP Andrew Futreal
Apr 30, 2011·Nature Reviews. Molecular Cell Biology·Ilio VitaleGuido Kroemer
Jan 8, 2013·Nature Chemical Biology·Gelin WangXiaodong Wang
Oct 9, 2013·Cancer Letters·Nandini SakurikarTimothy C Chambers
Jan 16, 2016·Oncotarget·Olivia SlossStephen Taylor

❮ Previous
Next ❯

Methods Mentioned

BETA
xenograft
gene knockdown
xenografts
immunoprecipitation
ELISA
biopsies
transfections
Hi-trap
Assay

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.